Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

• Main Authors: LU, Peng, HAO, Ximing, NURSE, Christina
• Format: Patent
• Language: English
• Published: 29.04.2021
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 mg every two weeks. Exemplary human patient subpopulations include female patients, patients less than 18 years old, between 40 and less than 65 years old, adolescent patients, patients who have had one or more prior laryngeal attacks, patients who have had between 1 and 2, 2 and 3, or more than 3 HAE attacks in the four weeks prior to the first dose of the first treatment period; and/or has received treatment with a C1 -inhibitor prior to the first treatment period.